- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05195827
Effect of PRM-125 on Ambulatory Blood Pressure
March 16, 2023 updated by: PRM Pharma, LLC
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults With Hypertension
Evaluation of Once-Daily PRM125 On Ambulatory Blood Pressure in Adults with Hypertension
Study Overview
Detailed Description
Approximately 60 subjects with primary hypertension are treated for 8 weeks with PRM125 to determine if Ambulatory Blood Pressure is changed.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Coral Gables, Florida, United States, 33134
- AMR
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- primary hypertension
Exclusion Criteria:
- medical conditions that preclude evaluation and/or adversely effect subject safety
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PRM125
|
Antihypertensive
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24 hour Systolic Blood Pressure
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in 24 hour Diastolic Blood Pressure
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 20, 2021
Primary Completion (Actual)
September 30, 2022
Study Completion (Actual)
November 30, 2022
Study Registration Dates
First Submitted
January 2, 2022
First Submitted That Met QC Criteria
January 13, 2022
First Posted (Actual)
January 19, 2022
Study Record Updates
Last Update Posted (Actual)
March 20, 2023
Last Update Submitted That Met QC Criteria
March 16, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CTD-3001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
Clinical Trials on PRM-125
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary FibrosisUnited States, Netherlands, Italy, Germany, Switzerland, Czechia, Spain
-
Hoffmann-La RocheCompletedIdiopathic Pulmonary FibrosisUnited States, Netherlands
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
Denver Health and Hospital AuthorityMicrosoft Corporation; EMC ConsultingCompletedDiabetes MellitusUnited States
-
Hoffmann-La RocheTerminatedIdiopathic Pulmonary FibrosisUnited States, Spain, France, Belgium, Australia, Denmark, Italy, Taiwan, Japan, Singapore, Turkey, Korea, Republic of, Germany, China, Ukraine, New Zealand, Netherlands, United Kingdom, Israel, Finland, Argentina, Czechia, Portugal, South... and more
-
Hoffmann-La RocheTerminatedIdiopathic Pulmonary FibrosisKorea, Republic of, United States, France, Israel, Spain, Belgium, Australia, Czechia, Denmark, Taiwan, Italy, Japan, Singapore, Turkey, Germany, China, New Zealand, Argentina, Portugal, South Africa, Hungary, Canada, Poland, Greece, Ne... and more
-
Oslo University HospitalUniversity of Melbourne; Norwegian Academy of MusicCompletedDelirium in Old Age | Delirium of Mixed Origin | Delirium Superimposed on Dementia | Delirium Confusional StateNorway
-
Neuropore Therapies Inc.CelerionCompletedHealthy VolunteersUnited States
-
McGill UniversityRecruiting
-
Hoffmann-La RocheCompletedPrimary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia MyelofibrosisUnited States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel